Who are Intravenous rhTNK-tPA's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fibrinolytic twice daily, Fibrinolytic once daily, low-dose tenecteplase intravenous thrombolysis, Intravenous thrombolysis agents, Fibrinolytic therapy, Recombinant human tissue plasminogen activator.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/intravenous-rhtnk-tpa.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Intravenous rhTNK-tPA — Competitive Intelligence Brief

Intravenous rhTNK-tPA (Intravenous rhTNK-tPA) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thrombolytic agent / Fibrinolytic. Area: Cardiovascular.

phase 3 Thrombolytic agent / Fibrinolytic Plasminogen / Fibrin Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Intravenous rhTNK-tPA (Intravenous rhTNK-tPA) — Xinqiao Hospital of Chongqing. rhTNK-tPA is a recombinant thrombolytic agent that dissolves blood clots by converting plasminogen to plasmin, enabling fibrin degradation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Intravenous rhTNK-tPA TARGET	Intravenous rhTNK-tPA	Xinqiao Hospital of Chongqing	phase 3	Thrombolytic agent / Fibrinolytic	Plasminogen / Fibrin
Fibrinolytic twice daily	Fibrinolytic twice daily	University of North Carolina, Chapel Hill	marketed	Fibrinolytic agent	Plasminogen / Fibrin
Fibrinolytic once daily	Fibrinolytic once daily	University of North Carolina, Chapel Hill	marketed	Fibrinolytic agent / Thrombolytic	Plasminogen / Fibrin
low-dose tenecteplase intravenous thrombolysis	low-dose tenecteplase intravenous thrombolysis	Southwest Hospital, China	marketed	Fibrinolytic agent / Tissue plasminogen activator (tPA)	Plasminogen / Fibrin
Intravenous thrombolysis agents	Intravenous thrombolysis agents	Second Affiliated Hospital, School of Medicine, Zhejiang University	phase 3	Thrombolytic agent / Fibrinolytic agent	Plasminogen / Fibrin
Fibrinolytic therapy	Fibrinolytic therapy	All India Institute of Medical Sciences	phase 3	Fibrinolytic agent / Thrombolytic	Plasminogen / Fibrin
Recombinant human tissue plasminogen activator	Recombinant human tissue plasminogen activator	Angde Biotech Pharmaceutical Co., Ltd.	phase 3	Fibrinolytic agent / Thrombolytic	Plasminogen / Fibrin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Thrombolytic agent / Fibrinolytic class)

Xinqiao Hospital of Chongqing · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Intravenous rhTNK-tPA — Competitive Intelligence Brief. https://druglandscape.com/ci/intravenous-rhtnk-tpa. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab